Paratek Pharmaceuticals Inc (PRTK) : Caxton Corp added new position in Paratek Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 18,909 shares of Paratek Pharmaceuticals Inc which is valued at $246,195 , the company said in a statement filed on Aug 15, 2016 with the SEC.Paratek Pharmaceuticals Inc makes up approximately 1.27% of Caxton Corp’s portfolio.
Other Hedge Funds, Including , Granite Investment Partners added PRTK to its portfolio by purchasing 47,776 company shares during the most recent quarter which is valued at $622,044. Paratek Pharmaceuticals Inc makes up approx 0.05% of Granite Investment Partners’s portfolio. Senzar Asset Management added PRTK to its portfolio by purchasing 134,219 company shares during the most recent quarter which is valued at $1,747,531. Paratek Pharmaceuticals Inc makes up approx 0.35% of Senzar Asset Management’s portfolio.Roumell Asset Management boosted its stake in PRTK in the latest quarter, The investment management firm added 73,008 additional shares and now holds a total of 290,136 shares of Paratek Pharmaceuticals Inc which is valued at $3,777,571. Paratek Pharmaceuticals Inc makes up approx 7.65% of Roumell Asset Management’s portfolio.Fmr reduced its stake in PRTK by selling 497,441 shares or 19.04% in the most recent quarter. The Hedge Fund company now holds 2,114,992 shares of PRTK which is valued at $27,537,196. Wealthtrust-arizona added PRTK to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $1,292.
Paratek Pharmaceuticals Inc closed down -0.11 points or -0.82% at $13.36 with 71,153 shares getting traded on Thursday. Post opening the session at $13.48, the shares hit an intraday low of $13.2 and an intraday high of $13.55 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Many Wall Street Analysts have commented on Paratek Pharmaceuticals Inc. Company shares were Reiterated by H.C. Wainwright on Jun 17, 2016 to “Buy”, Firm has raised the Price Target to $ 34 from a previous price target of $31 .
Paratek Pharmaceuticals Inc. (Paratek) formerly Transcept Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI) and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily tetracycline-derived compound designed for use in the treatment of acne and rosacea.